1 / 21

INA-RESPOND Test and Treat Study

INA-RESPOND Test and Treat Study. Dr. M. Karyana , MPH. Pusat Teknologi Terapan Kesehatan dan Epidemiologi Klinik, Badan Litbang Kesehatan – Kementerian Kesehatan RI Jakarta, 28 October 2014. 50. 45. 40. 35. 30. 25. 20. 15. 10. 5. 0. Global AIDS response – first 25 years.

sandra-carver
Download Presentation

INA-RESPOND Test and Treat Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. INA-RESPONDTest and Treat Study Dr. M. Karyana, MPH Pusat Teknologi Terapan Kesehatan dan Epidemiologi Klinik, Badan Litbang Kesehatan – Kementerian Kesehatan RI Jakarta, 28 October 2014

  2. 50 45 40 35 30 25 20 15 10 5 0 Global AIDS response – first 25 years First regimen to reduce MTCT of HIV First cases of unusual immune deficiency are identified among gay men in the USA June 1981 Global Fund to fight AIDS, TB and Malaria Acquired Immune Deficiency Syndrome (AIDS) defined WHO and UNAIDS launch the "3 x 5" initiative HAART launched Millions A heterosexual AIDS epidemic is revealed in Africa Brazil becomes the first developing country to provide ART HIV identified as cause of AIDS May 1983 The first HIV antibody test becomes available Global Network of People living with HIV/AIDS (GNP+) The WHO launches the Global Programme on AIDS President Bush announces PEPFAR The first therapy for AIDS - zidovudine/ AZT - is approved for use in the USA The UN General Assembly Special Session on HIV/AIDS UNAIDS created 2010 International AIDS Conference in Durban People living with HIV 1980 ‘81 ‘82 ‘83 ‘84 ‘85 ‘86 ‘87 ‘88 ‘89 ‘90 ‘91 ‘92 ‘93 ‘94 ‘95 ‘96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 The chronology above summarizes the ‘BIG Picture’ of AIDS – from the UNAIDS website Source: UNAIDS 2008

  3. Global number of people living with HIV & HIV-related deaths: Changes post-2005 Source: UNAIDS Global Report 2014

  4. Top 20 countries: People living with HIV South Africa Nigeria India Kenya Mozambique Zambia 14.7 million = 42% Uganda Tanzania Zimbabwe USA Zambia 21.5 million = 61% Malawi China Ethiopia Russia Brazil 25.6 million = 73% Indonesia Cameroon D.R.Congo Thailand Cote d’Ivoire 28 million = 80% Source: UNAIDS Global Report 2014

  5. ARV prophylaxis Treatment of STIs Male circumcision Microbicides for women Grosskurth H, Lancet 2000 AuvertB, PloS Med 2005 Gray R, Lancet 2007 Bailey R, Lancet 2007 Abdool Karim Q, Science 2010 Female Condoms Male Condoms HIV PREVENTION HIV Counselling and Testing Oral pre-exposure prophylaxis Coates T, Lancet 2000 Sweat M, Lancet 2011 Grant R, NEJM 2010 (MSM) Baeten J , NEJM 2012 (Couples) Paxton L, NEJM 2012 (Heterosexuals) Choopanya K, Lancet 2013 (IDU) Behavioural Intervention Post Exposure prophylaxis (PEP) Treatment for prevention Scheckter M, 2002 Cohen M, NEJM, 2011 Donnell D, Lancet 2010 Tanser, Science 2013 Note: PMTCT, Screening transfusions, Harm reduction, Universal precautions, etc. have not been included – this is on sexual transmission

  6. Clinical trial evidence for preventing HIV transmission – July 2013 Effect size (95%CI) Prevention in IDUs Bangkok Tenofovir Study - Daily oral PrEP for IDUs 49% (10; 72) HPTN 052 - ART for prevention 96% (73; 99) PartnersPrEP - Daily PrEP for discordant couples 73% (49; 85) TDF2 - Daily PrEP for heterosexual men and women 62% (22; 84) Medical male circumcision 54% (38; 66) Sexual transmission prevention iPrEX - Daily PrEP for MSM 44% (15; 63) Mwanza - STD treatment 42% (21; 58) CAPRISA 004 - Coital microbicide for women 39% (6; 60) RV144 - HIV vaccine 31% (1; 51) 15% (-21; 40) MTN 003 - Daily microbicide for women FEM-PrEP - Daily oral PrEP for women 6% (-52; 41) Effectiveness (%) • Source: adapted from Abdool Karim SS.Lancet 2013

  7. Audience with the Minister of Health

  8. Study Title • Indonesia Prevention of HIV and AIDS Transmission by Increasing Testing and Prompt Treatment

  9. Research Question “Does a strategy of combination HIV prevention including universal HIV testing and treatment reduce HIV transmission (incidence) at community level?”

  10. Hypothesis • Universal voluntary HIV testing with appropriate combination prevention offered to all those testing HIV negative - in addition to immediate ART for all those testing HIV positive - will have a substantial impact on HIV incidence at population level

  11. Lancet 2009 373: 48-57

  12. Why is a Study Needed? • Not known whether a UTT intervention can be delivered with high acceptability • Many uncertainties in model parameters • Population-level impact of intervention package is not known • A rigorously designed study can measure the costs and benefits of this strategy and provide reliable evidence on cost-effectiveness for health policy makers

  13. Design Issues • What should the combination prevention package contain? • HCT- universal uptake • Linkage to care and provision of ART • Sexual risk reduction • PMTCT • STI • TB • What scenarios would be useful to policy makers? • Universal test and treat Vs current • Costs of each • Delivery under routine programmatic conditions as far as possible

  14. Study Design

  15. Study Coverage

  16. Measuring HIV Incidence • HIV incidence will be estimated by assessing HIV seroconversion in a longitudinal cohort Advantages • Gold standard approach for HIV incidence estimation • Uses routine HIV test methods • Provides interim and cumulative incidence estimates • Cohort allows for measurement of other indicators Disadvantages • Requires longitudinal cohort follow-up • Impacted by loss-to-follow up, including differential loss to follow-up • Complex sampling is needed to ensure that the cohort reflects the population as a whole

  17. Intervention Package Facilitated by CHiPs Universal testing: annual door-to-door HCT Service promotion and referral for - HIV care for HIV +ve including PMTCT - TB - STI Follow-up on referral • Support for: • Retention in care • Adherence • to treatment Health centre Universal treatment for HIV +ve irrespective of CD4 count CHiPs: Community HIV-care Providers PMTCT: Prevention of Mother to Child Transmission TB: Tuberculosis STI: Sexually Transmitted Infections

  18. What is the influence of process parameters? treatment drop-out/failure efficacy of ART in blocking transmission • Relative reduction in 3-year HIV incidence in arms A and B • Linear model Effect of counselling on infectivity uptake of testing, ART Delays in linkage to care % sex acts with partners from other communities

  19. This study will use a cohort measure of HIV incidence to assess the effectiveness of a package of combination HIV prevention including a “universal test and treat” approach Adoption of new consolidated WHO guidelines should only moderately affect ability to detect differences between arms in the study Primary outcome mostly depends on Community-level changes in behaviours Efficacy of ART in blocking transmission (adherence) Uptake of HIV testing and treatment Conclusions

  20. Supported by: The National Institute of Allergy and Infectious Diseases (NIAID), the U.S. National Institutes of Health (NIH) National Institutes of Health Research and Development (NIHRD), the Indonesia Ministry of Health Acknowledgement

  21. THANK YOU TERIMA KASIH MATUR SUKSMA MATUR SUWUN HATUR NUHUN

More Related